Skip to Main Content

Advertisement

Skip Nav Destination

MDS & Myeloproliferative Neoplasms

December 20, 2021

A collection of features and news articles published in ASH Clinical News related to myelodysplastic syndromes and myeloproliferative neoplasms.

Cardiovascular Disease and Myeloproliferative Neoplasms

The association between myeloproliferative neoplasms (MPNs) and an increased risk of both thrombotic and hemorrhagic complications has been recognized for some time, ...

Momelotinib Bests Danazol in Symptomatic Patients With Anemic Myelofibrosis

In symptomatic patients with anemia of myelofibrosis (MF), momelotinib was superior to danazol for total symptom score (TSS) response, transfusion independence (TI) rate, and splenic response rate...

SRSF2 Mutation Status May Predict Romiplostim Treatment Response in Lower-Risk MDS

At the time of diagnosis, around half of patients with lower-risk myelodysplastic syndromes (MDS) present with thrombocytopenia, which is associated with shortened survival...

Continuation Trial Confirms Symptom Reduction With Ropeginterferon Alfa-2b Therapy for PV

Researchers confirmed ropeginterferon alfa-2b’s power to effectively reduce symptoms in patients with polycythemia vera...

Magrolimab Plus Azacitidine Elicits Response in Untreated, Higher Risk MDS

Magrolimab, a monoclonal antibody against CD47, induces macrophage-mediated phagocytosis of tumor cells. Its effect appears to be synergistic with the chemotherapeutic agent azacitidine...

ASXL1 Mutations May Predict Response After Venetoclax and HMA Therapy for MDS

The presence of ASXL1 mutations predicted favorable response and survival after venetoclax and hypomethylating agent (HMA) therapy in patients with myelodysplastic syndromes (MDS) with excess blasts...

Cell Architecture Drives MDS and Progression, Could Guide Second-Line Treatment

The hematopoietic cell architecture in myelodysplastic syndromes (MDS) may have the potential to predict disease progression and guide use of second-line treatment after hypomethylating agent (HMA)-based therapy failure...

Reduced Intensity Transplantation Shows Excellent Survival but Higher Relapse in Accelerated-Phase Myelofibrosis

A study of patients with primary or post-essential thrombocythemia (PET) and post-polycythemia vera (PPV) myelofibrosis found that those treated with reduced intensity transplantation had im­proved survival overall...

Adding Durvalumab to Chemotherapy Does Not Improve Outcomes in MDS

Combining the checkpoint inhibitor durvalumab with standard of care azacitidine did not improve the response rate among treatment-naïve patients with higher-risk myelodysplastic syndromes...

Pegylated Interferon Alpha and Hydroxyurea Show Similar Efficacy in Treatment-Naïve, High-Risk ET and PV

Pegylated interferon (PEG-IFN) alpha was equally effective as hydroxyurea at normalizing blood counts and reducing thrombotic events in patients with high-risk essential thrombocythemia (ET) or polycythemia vera...

Advertisement

Connect with us:

CURRENT ISSUE
September 2022

Advertisement

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement